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Abstract
Host immune responses at the site of Mycobacterium tuberculosis (Mtb) infection can mediate 
pathogenesis of tuberculosis (TB) and onward transmission of infection. We hypothesized that 
pathological immune responses would be enriched at the site of host-pathogen interactions 
modelled by a standardized tuberculin skin test (TST) challenge in patients with active TB 
compared to those without disease, and interrogated immune responses by genome-wide 
transcriptional profiling. We show exaggerated interleukin (IL)-17A and Th17 responses among 
48 individuals with active TB compared to 191 with latent TB infection, associated with increased 
neutrophil recruitment and matrix metalloproteinase-1 expression, both involved in TB 
pathogenesis. Curative antimicrobial treatment reversed these observed changes. Increased IL-1β 
and IL-6 responses to mycobacterial stimulation were evident in both circulating monocytes and in 
molecular changes at the site of TST in individuals with active TB, supporting a model in which 
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monocyte-derived IL-1β and IL-6 promote Th17 differentiation within tissues. Modulation of 
these cytokine pathways may provide a rational strategy for host-directed therapy in active TB.
Introduction
Mycobacterium tuberculosis (Mtb) infection results in a spectrum of clinical outcomes, from 
asymptomatic latent infection to symptomatic disease. The focus of host-pathogen 
interactions is characterized histologically by granulomatous inflammation that may restrict 
bacterial growth, but this response can also result in tissue damage that promotes 
transmission of infection to other individuals (1, 2). The distinctions that tip the balance 
between protective and pathogenic immune responses remain a fundamental question in 
tuberculosis research. This knowledge is expected to inform rational vaccine design by 
identifying correlates of disease protection. However, understanding the molecular 
components that drive immunopathology can also guide development of host-directed 
therapies that attenuate tissue damage, limit morbidity and mortality, and reduce onward 
transmission. In addition, this approach may provide an adjuvant to antimicrobial therapy, 
allowing reduced duration of antimicrobial treatment and mitigating against increasing 
antimicrobial resistance (3).
Chronic inflammatory pathology at the site of human tuberculosis (TB) infection has been 
the subject of extensive descriptive studies, but discriminating between protective and 
pathological immune responses has been limited to comparing leukocyte phenotype and 
function in blood from Mtb-exposed patients with and without active disease (1). We have 
shown that genome-wide transcriptional profiling of biopsies of the tuberculin skin test 
(TST) can be used to make comprehensive molecular and systems level assessment of in 
vivo immune responses at the site of standardized host-pathogen interactions, including 
Mtb-infected lungs and lymph nodes (4–7). Importantly, the transcripts enriched within TST 
biopsies reflected the genome-wide variation in molecular pathology at the site of TB 
disease (5, 7), suggesting that the TST represents a valuable surrogate for assessing TB 
immunopathogenesis in humans in vivo.
In the present study we aimed to test the hypothesis that immune responses at the site of 
host-pathogen interactions, modelled by the TST, would reveal immunopathologic responses 
in patients with active TB that were absent in individuals with equivalent immune memory 
for Mtb but without disease. We used in vivo transcriptional responses at the site of TST to 
deconvolute differential cellular infiltration and functional cytokine activity, identifying in 
active TB the enrichment of molecular changes associated with immunopathology. We 
supplemented these findings with cytokine responses from ex vivo-stimulated monocytes to 
derive a mechanistic model of disease pathogenesis centered around elevated interleukin 
(IL)-17A activity as a driver of tissue damage in TB disease, in turn identifying a putative 
target for host-directed interventions.
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Immune responses at the site of TST in active and latent TB
The TST has been extensively used to identify patients with T cell memory for 
mycobacterial antigens, but the magnitude of the clinical response does not differentiate 
infected individuals with and without active TB disease (1). We sought to test the hypothesis 
that molecular profiling of the TST may identify elements of the recall response that are 
specifically associated with disease. We undertook 48-hour TSTs in 48 human 
immunodeficiency virus (HIV)-negative patients with microbiologically-confirmed 
pulmonary TB disease within the first month of treatment (‘active TB’, cohort 1) to identify 
disease-associated responses. We compared these to TST responses in 191 HIV-negative 
patients with latent TB, representing non-disease associated recall responses. The latent TB 
cohort was defined by a positive peripheral blood interferon gamma release assay (IGRA) 
and absence of clinical and radiological evidence of active TB disease (table S1). The active 
TB cohort was moderately over-represented by male recruits, whereas Asian patients were 
more frequent in the latent cohort. However, the age distribution was comparable between 
the two groups (Table 1). As expected, clinical induration in response to the TST was not 
different between the two groups (Fig. 1A), hitherto interpreted to reflect comparable cell-
mediated immune memory.
In comparison to skin biopsies from the site of control saline injection, 7065 genes showed 
increased expression in response to the TST in at least one study group (Data File S1). Of 
these, 5743 were present in both groups (fig. S1A). Systems level assessment of the shared 
response revealed the prototypic cell mediated immune responses which we had previously 
described in the TST (fig. S1B) (5). We have previously shown that molecular changes in the 
TST reflect closely host responses at the site of TB disease (5, 7), and we extended these 
analyses by demonstrating the shared TST response to be enriched in the wall of Mtb-
infected cavities relative to both healthy lungs and macroscopically normal adjacent lung 
tissue sections (8) (fig. S1C). Pairwise assessment of expression of the integrated list of 
transcripts that were enriched in either patient group showed these to be correlated, 
consistent with the hypothesis that at the level of individual molecules, most responses do 
not discriminate between the two groups (fig. S1D).
A proportion of transcripts were differentially enriched between the two groups (Fig. 1B, 
Data File S1). We focused on 151 of these genes that were expressed more than twofold 
higher in patients with active TB compared to patients with latent TB (Fig. 1B and C). 
Amongst these, Reactome Pathway Analysis identified enrichment for matrix 
metalloproteinases (MMPs), such as MMP-1, that has been strongly implicated in 
pathogenic degradation of the extracellular matrix in TB (9), as well as for beta defensins 
that exert both antimicrobial functions and also provide a chemotactic gradient for CCR2-
expressing cells, including neutrophils (10) (Fig. 1D). The TST in active TB was also 
enriched for other genes that are chemotactic for neutrophils, such as CXCL1, CXCL8 and 
S100A9 (Fig. 1D) (11, 12).
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Elevated IL-17A responses in active TB
We hypothesized that the genes over-expressed in active TB were regulated by common 
upstream signals in the tissue environment. To test this hypothesis, we compared the 
predicted upstream regulators of enriched transcripts in the TST of active and latent TB 
patients using Ingenuity Pathway Analysis (6). This analysis suggested that interferon (IFN)-
γ, tumor necrosis factor (TNF)-α and IL-1 family cytokines were predicted to be upstream 
signals for genes enriched in both active and latent TB. In contrast, IL-17A, oncostatin M 
(OSM) and IL-6 were predicted to induce the expression of genes uniquely enriched in 
active TB (Fig. 2A). We hypothesized that the predicted upstream signals would also be 
enriched at the gene level in the TST of patients with active TB. IL-17A and IL-17F, a 
closely related member of this cytokine family that binds the same receptor and exerts 
similar functions, were enriched in active TB (Fig. 2B) (11). In contrast, we found no 
difference in the expression of OSM or IL-6 transcripts (Fig. 2B). We also evaluated 
expression of IL-22, representing another cytokine with closely related biological function to 
IL-17A and IL-17F (13), but this was not differentially enriched in active TB (Fig. 2B).
To further test the functional relevance of the differences in IL-17A/F expression between 
active and latent TB, we extended our analyses to look more broadly at genes downstream of 
IL-17A. We derived gene expression modules for the specific transcriptional response of 
keratinocytes (KC) to IL-17A or other cytokines (14, 15) (Data File S2). We used the 
geometric mean expression of these modules as a biosignature to quantify cytokine activity 
in vivo. We confirmed that the resulting transcriptional modules were both sensitive and 
specific for their cognate stimuli by assessing their expression in other independent datasets 
(fig. S2). We then compared the expression of these cytokine-specific transcriptional 
modules in the TST transcriptomes as a measure of the functional activity of each cytokine. 
The IL-17A-induced gene module was increased in the TST of people with active TB 
compared to that of latent TB, but expression of IFN-γ, IFN-α, or TNF-α inducible gene 
modules was not different between the two groups (Fig. 3A).
A key function of IL-17A/F is to promote neutrophil recruitment via induction of neutrophil 
chemokines (16). Importantly, neutrophils also contribute to the immunopathology of TB 
(12, 17–20). Therefore, we tested the hypothesis that the TST in active TB would reveal 
increased neutrophil recruitment, compared to that of patients with latent TB. Consistent 
with this hypothesis, we found higher expression of a neutrophil transcriptional module, 
previously validated as a measure of the number of neutrophils (21), in the TST 
transcriptome of people with active TB compared to people with latent TB (Fig. 3B). We 
verified this enrichment of neutrophils in active TB using an independent immune cell 
deconvolution strategy (22) (fig. S3), a finding which was consistent with the higher gene 
expression of the IL-17A-inducible chemokines CXCL1, CXCL8 and S100A9 in active TB 
that promote neutrophil recruitment to sites of inflammation (11, 12) (Fig. 1D). In contrast, 
accumulation of T, B, and natural killer (NK) cells, quantified by expression of their 
respective transcriptional modules, (21), was greater in the TST of patients with latent TB 
compared to active TB (Fig. 3B).
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Increased frequency of Th17 cells in active TB TST responses
IL-17A/F are predominantly produced by conventional Th17 cells, gamma delta (γδ) T cells 
and neutrophils (11). Immunohistochemistry revealed that in the TST of people with active 
TB, IL-17F, originated predominantly from mononuclear cells, rather than from 
polymorphonuclear cells (Fig. 4A). Therefore, we tested the hypothesis that Th17 cells were 
enriched in the TST of people with active TB compared to latent TB. We derived 
transcriptional modules specific for differentially polarized CD4+ Th subsets from a 
published dataset (23) (Data File S2) and demonstrated their specificity in an independent 
dataset (24) (fig. S4A and B). We further validated the Th17 module within skin biopsies of 
patients with psoriasis vulgaris, representing an alternative Th17-mediated inflammatory 
condition (25), showing that the transcriptional response to IL-17A positively correlated 
with the expression of the Th17 module (fig. S4C). Patients with active and latent TB 
revealed comparable expression of a Th1-associated transcriptional module, whereas 
expression of the Th17 module was increased in patients with active TB (Fig. 4B).
IL-17A functional activity and Th17 cells are present at the site of TB disease
Having established that upregulation of IL-17A/F and its downstream functional activity was 
exaggerated in the tissue recall response to Mtb among people with active TB compared to 
those with latent TB, we sought to extend previous reports that IL-17A/F activity was also 
evident at the natural site of TB disease as previously described (8, 26). The transcriptome of 
human TB granuloma (27) showed an enrichment of T cells, Th17 cells and IL-17A induced 
genes compared to normal lung tissue (Fig. 4C). In addition, we examined the transcriptome 
of human Mtb-infected lymph node samples compared to unspecified ‘reactive’ causes of 
lymphadenopathy devoid of granulomatous inflammation or malignancy (28). We observed 
enrichment for our pan-T cell transcriptional module in reactive lymph nodes compared to 
TB lymphadenitis; however, the Th17 module and the module of IL-17A-induced genes was 
enriched within Mtb-infected lymph nodes (Fig. 4D). Overall, our data establish that an 
increased Th17 transcriptional signature and elevated IL-17A activity, which we observed in 
the TST in active TB, are also evident at the site of TB disease.
Impact of curative antibiotic treatment, disease burden and demographics on IL-17A 
activity in active TB
We hypothesized that exaggerated IL-17A/F immune responses at the site of host-pathogen 
interactions in active TB may represent a maladaptive immune response associated with 
chronic immune stimulation arising from the failure to clear Mtb. To address this question 
experimentally, we tested the hypothesis that curative treatment for active TB would reverse 
the exaggerated IL-17A/F transcriptional responses in the TST challenge. We compared TST 
responses in a second cohort of patients with active TB in the first month of treatment 
(‘active TB’ cohort 2) to a second cohort of patients within two years of curative TB 
treatment (‘cured TB’) (Table 1). TST response induration was comparable between these 
cohorts (Fig. 5A). However, consistent with our hypothesis, the TST of cured TB patients 
showed reduced expression of IL17A and IL17F genes (fig. S5A), IL-17F protein (fig. S5B 
and C) and IL-17A inducible genes, as a measure of functional cytokine bioactivity (Fig. 
5B). In addition, Th17- and neutrophil-associated transcriptional modules also showed lower 
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expression in cured TB (Fig. 5B and C, fig. S3). Likewise, MMP1 gene expression and 
protein at the site of inflammatory infiltrates in the TST were also reduced in cured 
compared to active TB (fig. S5D to G). In contrast, there was no difference in expression of 
IFNG or TNF genes, in functional activity of IFN-γ, type I IFN, or TNF-α, or in expression 
of pan-T cell or Th1-associated transcriptional modules (Fig. 5B to D and fig. S5A).
Rapid changes in the peripheral blood transcriptome associated with active TB have been 
reported (29). Therefore, we tested the hypothesis that IL-17A inducible responses in the 
TST would also be diminished rapidly. TST sampling in active TB patients was performed at 
different time points within the first month of treatment (median 19 days, IQR 13-26 for 
cohort 1 and median 11 days, IQR 5-28 days for cohort 2). We did not observe a decrease in 
IL-17A bioactivity or Th17 responses over this time period of TB treatment (Fig. 5E). These 
findings suggest that the mechanisms that drive exaggerated IL-17A bioactivity in active TB 
persist for at least one month after the initiation of curative treatment. Participants with 
cured TB were assessed at different time points following completion of TB treatment, but 
we found no relationship between this time interval and functional IL-17A bioactivity or 
Th17 accumulation in the TST (fig. S6), indicating resolution of the processes that drive 
exaggerated IL-17A responses by completion of treatment.
We also considered whether the induction of IL-17A responses was associated with the 
burden of TB disease. For active TB patients in cohort 1, we had access to radiology and 
microbiology data, but found no association with radiological severity scores or 
microbiological load at the time of diagnosis (fig. S7). Similarly, there was no association 
between Th17 module or MMP-1 gene expression and these measures of TB burden (fig. 
S7). In addition, whereas all patients in active TB cohort 1 had pulmonary TB, cohort 2 
included patients with extrapulmonary disease, but we found no difference in IL-17A or 
Th17 responses between people with pulmonary and extrapulmonary TB (fig. S8). 
Furthermore, in the larger cohort 1, sensitivity analyses revealed elevated IL-17A activity 
and Th17 responses in active TB to be independent of sex (fig. S9A) and ethnicity (fig. 
S9B). Active TB cohort 1 and the comparator latent TB cohort were all recruited from the 
United Kingdom (UK), but active TB cohort 2 consisted of patients from the UK and South 
Africa. There was no difference in IL-17A and Th17 responses among active TB patients 
recruited from the geographically distinct sites (fig. S10A). In a further sensitivity analysis 
among active TB cohort 2 restricted only to patients recruited from the UK, there remained 
differences in these responses among patients with active and cured TB (fig. S10B).
Drivers of elevated IL-17A activity in active TB
To investigate the mechanism for increased Th17 responses in the TST of patients with 
active TB, we tested the hypothesis that disease was associated with increased frequency of 
circulating Th17 cells. We assessed the expression of the Th1 and Th17 subset modules in 
the transcriptome of peripheral blood mononuclear cells (PBMC) from individuals with 
active TB disease or individuals with latent TB, stimulated overnight with Mtb purified 
protein derivative (PPD) (30). In contrast to the evident differences at the site of the TST, 
expression of the Th17 associated transcriptional module in PBMC was not different 
between groups (Fig. 6A). We extended this analysis by performing intracellular cytokine 
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staining in PBMC from subsets of active and latent TB individuals from cohort 1 following 
stimulation with PPD or nonspecific T cell activation with phorbol 12-myristate 13-acetate 
(PMA) and ionomycin. Neither stimulus revealed a propensity for CD4+ or CD8+ T cells in 
active TB to secrete greater amounts of IL-17A or IFN-γ (Fig. 6B and C). We interpret these 
results to mean that increased functional IL-17A bioactivity in the TST of patients with 
active TB was not due to increased recruitment of circulating T cells already committed to 
Th17 differentiation.
Next, we explored the hypothesis that active TB may result in an increase in monocytes 
which could drive Th17 differentiation within the tissue response modelled by the TST. 
Several studies have demonstrated that systemic inflammatory perturbation, including 
Bacillus Calmette-Guérin (BCG) vaccination, can condition monocytes to differentially 
respond to secondary stimuli (31, 32). To test this hypothesis, we compared primary 
transcriptional responses of CD14+ monocytes to 4 hours PPD stimulation from individuals 
with active and latent TB. The baseline transcriptome of these cells did not identify any 
differences between the two groups, but following PPD stimulation, the transcriptional 
responses diverged (fig. S11A), inducing the upregulation of almost twice as many genes in 
active TB compared to latent TB (Fig. 7A and Data File S1). These included IL1A, IL1B 
and IL6 genes, encoding cytokines that promote Th17 differentiation (33) (Fig. 7B). These 
findings were replicated by qRT-PCR (fig. S11B) and complemented by increased secretion 
of IL-6 protein in monocytes from patients with active TB (Fig. 7C). Consistent, with these 
findings ex vivo, we observed increased functional IL-1β and IL-6 cytokine activity in the 
TST of patients with active TB compared to either latent or cured TB (Fig. 7D), using 
transcriptional modules composed of IL-1β (fig. S12 and Data File S2) (34, 35) and IL-6 
(36) inducible genes. Taken together, these data are consistent with a model in which 
exaggerated Th17 responses at the site of host-pathogen interactions in active TB are driven 
by recruitment of IL-1β or IL-6 producing monocytes (fig. S13).
Discussion
We combine a standardized human antigen challenge model in which we are able to measure 
the functional activity of specific immune response pathways, with two independent cohorts 
of active TB and two separate comparator populations of latent and cured infection, to 
provide compelling evidence that in vivo IL-17A/F responses are exaggerated in active 
disease. Our findings suggest an important role for these responses in the 
immunopathogenesis of TB, which may be amenable to therapeutic targeting.
IL-17A/F contribute to host defence against bacterial and fungal pathogens, as demonstrated 
by mice deficient for IL-17A/F or IL-17 receptors, and by humans with inborn errors of 
IL-17 immunity (16). They are also strongly implicated in the immunopathology of chronic 
inflammatory diseases, such as psoriasis (16, 37). Animal models suggest a protective role 
for IL-17A/F following BCG vaccination (38) and in the early stages of Mtb infection (39–
42) by promoting T cell chemotaxis to lymphoid follicles in Mtb-infected lungs (39) and by 
preventing formation of necrotic granuloma (43). However, in mice rendered susceptible to 
TB disease as a result of IFN-γ deficiency, and in mice receiving repeated BCG vaccinations 
to model persistent stimulation, IL-17A/F responses drive neutrophil-mediated pathology 
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(12, 17–19). Furthermore, IL-17A/F can promote S100A8/9 and MMP-1 secretion by 
stromal cells (44, 45) and is strongly associated with neutrophil infiltration in chronically 
inflamed psoriatic lesions (46). We infer that IL-17A/F responses may play a dichotomous 
role in TB, contributing to protection in early infection, but driving pathology when the 
infection is not controlled and bacterial replication promotes chronic immune stimulation. 
Additional support for this model is evident in IL-27R deficient mice, which exhibit 
exaggerated Th17 responses because they lack IL-27 inhibition of RORγT (47). These mice 
show enhanced clearance of Mtb, but also increased immunopathology dependent on 
IL-17A. Interestingly, a human candidate gene study identified host genetic variation 
associated with increased secretion of IL-17A to be correlated with both protection from 
incident TB but also more severe TB disease (48). Taken together, we hypothesize that 
exaggerated IL-17A/F recall responses in active TB are the consequence of chronic 
multibacillary infection that mediates increased pathology in established TB disease.
Evolutionary conservation of Mtb-targeting T cell epitopes strongly suggests that T cell 
responses promote immunopathology (49), and that their negative regulation is critical to 
preventing disease manifestation (50). Our data support the hypothesis that exaggerated 
IL-17A/F responses arise from Th17 cells, but they do not unequivocally exclude other 
cellular sources. Using both transcriptional profiling and flow cytometry of circulating cells 
in blood, we did not observe evidence for increased circulating Mtb-reactive Th17 cells in 
active TB, consistent with most other studies (51–53). We note one previous report of 
increased concentrations of NKT cell derived IL-17 protein in active TB that reduced 
following treatment (54). We did observe Th17 cell enrichment and IL-17A bioactivity at the 
site of TB disease, also consistent with other reports (8, 26, 41, 42, 52). We note that some 
studies have not been able to detect increased IL-17 protein or Th17 cells from the 
inflammatory exudate associated with pericardial and pleural TB (51, 55). We speculate that 
these discrepancies may arise from inadequate sensitivity of the approach used to detect 
IL-17 cytokines and Th17 cells, or biological confounding related to the site of disease or 
the timing of sampling. Overall, however, our findings are supported by the majority of 
previous literature and suggest a model whereby differential Th17 responses observed within 
the TST are not governed by increased frequency of circulating Th17 cells, but by immune 
signalling networks within the tissue microenvironment after T cell recruitment.
We implicate circulating CD14+ monocytes as key players in promoting IL-17A responses at 
the site of host-pathogen interactions. We propose that infiltrating monocytes from patients 
with active TB produce elevated concentrations of cytokines, particularly IL-1β or IL-6, 
known to promote the differentiation of T cells to a Th17 phenotype (33). Trained immunity 
is increasingly reported to modulate immune responses by myeloid cells post-BCG 
vaccination (31, 32), but this was not seen in unstimulated myeloid progenitors following 
systemic Mtb infection in mice (56). We did not see differences in the baseline transcriptome 
of monocytes in active TB that might be expected as a result of epigenetic modifications 
associated with trained immunity. Nonetheless, modulation of transcriptional responses was 
observed following mycobacterial stimulation. This included increased IL-1β and IL-6 
responses that have been implicated in both trained immunity and Th17 differentiation (31, 
33, 57, 58). The mechanisms regulating this conditioned response in active TB will require 
further investigation to evaluate the potential roles of epigenetic and metabolic 
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reprogramming (31, 57), and that of bacterial factors such as ESX-1 mediated secretion of 
ESAT-6 known to promote IL-6 and Th17 responses (59–61). However, we propose that the 
same molecular responses that are beneficial in the early stages of infection become 
dysregulated by the unresolved focus of infection in active TB disease, ultimately driving 
IL-17A/F-mediated immunopathology. IL-1 responses contribute to protection against Mtb 
challenge in mouse models (62), but exaggerated IL-1 and IL-6 responses promote 
immunopathology in other chronic inflammatory conditions, such as juvenile idiopathic 
arthritis and rheumatoid arthritis (36). Of note, increased TB disease severity has been linked 
to genetic polymorphisms associated with elevated IL-1β and IL-17A secretion (48, 63), as 
well as increased activity of the IL-6 axis in vivo (64).
The large active TB sample size in cohort 1 allowed us to explore and exclude contributions 
from sex and ethnicity. Despite the smaller sample size, we observed no differences in IL-17 
activity between pulmonary and extrapulmonary TB in cohort 2, but these analyses will 
require validation in larger populations. We also observed no relationship between IL-17A 
responses and disease burden, as determined by plain chest radiography or sputum bacterial 
load. However, variation in both measures of severity is subject to confounding by duration 
of illness and may represent the volume of diseased tissue rather than the degree to which 
immune responses are skewed towards pathogenesis. Nevertheless, the maintenance of 
elevated IL-17A activity in the first month of treatment demonstrates that dynamic immune 
responses measured in our experimental model are independent of the immediate 
immunological changes that follow the onset of treatment, reflected in blood transcriptomic 
data (29). A future research priority will be to identify the point at which the effect of 
disease on IL-17A/F responses is reversed during recovery with antimicrobial treatment, in 
order to define a therapeutic window for host-directed immunomodulation in active TB 
disease. Sampling the TST response at time points beyond 48 hours may also provide 
insights into additional differences in homeostatic pathways between active and latent TB.
Our study has several limitations. The cross-sectional nature renders our observations 
susceptible to unmeasured confounding variables. We negated these risks through the 
inclusion of multiple cohorts to corroborate the generalizability of our findings. We have not 
established a causal association between exaggerated IL-17A responses and disease 
pathology or between elevated IL-1β or IL-6 monocyte responses and IL-17A bioactivity at 
the site of host-pathogen interaction. These associations are supported by multiple studies in 
the literature (12, 17–19, 23, 33, 65, 66), but in vivo experiments in non-human primates and 
interventional studies in humans are required to test the functional relationship between 
these cytokines in TB disease. Our bioinformatic analysis of transcriptional changes in 
tissues was validated by independently derived transcriptional signatures to enumerate 
immune cells and functional cytokine activity in vivo. Nonetheless, cellular- and protein-
level data to further corroborate our findings will be sought in future work. In addition, we 
were not able to establish the relative contribution made by specific lymphocyte populations, 
such as γδ T cells or type 3 innate lymphoid cells (ILC3), to IL-17A/F expression as 
previously reported (40, 42, 54, 67, 68). Future studies will require single cell resolution, 
using single cell sequencing or multiplex RNA FISH assays, to confirm the source and 
spatial organisation of exaggerated IL-17A/F responses in this model, as well as to 
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determine whether active TB shows enrichment for ‘pathogenic’ Th17 cells that express 
both IFN-γ and IL-17A/F (69).
Taken together, our data implicate IL-17A immune responses as drivers of tissue 
immunopathology in TB. We propose that therapeutic targeting of these responses as an 
adjunct to antimicrobial therapy in active TB offers strategies to ameliorate tissue damage 
and further reduce transmission of infection by promoting immune homeostasis. The 
availability of therapies that block IL-17A/F cytokine pathways, or upstream signals such as 
the IL-1α/β and IL-6 axes, (37, 70), offers invaluable opportunities to transition from proof 
of concept pre-clinical studies to first-in-human experiments. These studies are needed to 
establish the functional interaction between these cytokines and their causal role in the 
pathogenesis of human TB as a prelude to clinical trials for therapeutic benefit.
Methods
Study design
The aim of the study was to identify immunopathological responses in active TB. We 
hypothesized that in individuals with active TB, the tissue recall response to Mtb antigens 
using the standardized human TST challenge model (4–7), would be enriched for immune 
responses that drive tissue damage. The first objective was to identify cytokines that 
regulated the expression of genes over-expressed in the TST in active TB compared to non-
diseased latent TB. Having identified IL-17A/F to be this cytokine, the second objective was 
to validate this finding experimentally by independently generating transcriptional modules 
that represented the cellular response to cytokine stimulation, and then demonstrating 
elevated IL-17A/F responses in the TST in active TB. The third objective was to define the 
potential source of IL-17A/F by generating modules for different CD4 T helper cell 
phenotypes and demonstrating enrichment for Th17 cells in active TB. Our fourth objective 
was to demonstrate that IL-17A/F responses were a feature of tissue responses at the site of 
active TB disease, making use of the transcriptome of Mtb infected lung granuloma and 
lymph nodes. Our fifth objective was to determine the role of curative antibiotic treatment on 
attenuating elevated IL-17A/F responses observed in active TB. Finally, our sixth objective 
was to identify putative mechanisms that drove elevated Th17 cell enrichment and IL-17A/F 
responses. We tested the hypothesis that circulating monocytes in active TB were 
conditioned to induce greater IL-1β and IL-6 responses following Mtb antigen stimulation, 
generating a local tissue environment that favoured Th17 differentiation at the site of host-
pathogen interaction in TB disease.
Sample sizes are provided in Table 1 and are larger than those used to identify and reproduce 
differences in gene expression between study populations using the TST model in our 
previous studies (4, 5, 7). Recruitment to the study was performed strictly according to the 
inclusion criteria set out in table S1, and no randomisation was necessary. Details of 
experimental replicates are provided in accompanying figures. Gene expression analyses 
were not performed blinded, but all immunostaining and quantification was performed by 
investigators blinded to the study groups being compared.
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Active TB cohort 1 was recruited from TB clinics in London, UK (figs 1-4 & 6). This 
population was compared to individuals with latent TB recruited from TB clinics in London, 
UK and Lima, Peru. Active TB cohort 2 that formed the basis of the analyses in figs 5-6 was 
the HIV seronegative cohort described in our previous publication (5), recruited from TB 
clinics in London, UK and Cape Town, South Africa. The comparator ‘Cured TB’ group was 
an independent cohort recruited from TB clinics in London, UK and Lima, Peru. Inclusion/
exclusion criteria and characteristics of the study groups are described in table S1. On 
recruitment to the study, all participants provided a peripheral blood sample and underwent a 
tuberculin skin test or control saline injection, and the extent of inflammatory induration was 
measured at 48 hours and then subjected to two adjacent punch biopsies for transcriptional 
profiling or histology as previously described (5, 6). Radiological severity scores were 
derived according to established protocols (71).
The recruitment of patients with active, cured and latent TB was approved by UK National 
Research Ethics Committees (reference numbers: 14/LO/0505, 16/LO/0776 and 18/LO/
0680), University of Cape Town Human Research Ethics Committee (reference number: 
580/2012). and by Universidad Peruana Cayetano Heredia Institutional Ethics Committee 
(reference number: 62349) and was subject to written informed consent.
TST sample processing for transcriptional profiling
Tuberculin skin tests (TSTs) were performed and biopsies from the site of TST were 
collected as previously described (5). Skin samples from all participants were stored in 
RNAlater at −70°C after collection. For processing, TST samples were equilibrated to room 
temperature for 30 minutes before being transferred to CK14 lysing kit tubes (Bertin 
Instruments) containing 350εI of Buffer RLT (Qiagen) supplemented with 1% 2-
Mercaptoethanol (Sigma). Tubes were pulsed for 6 cycles on a Precellys Evolution 
homogenizer (Bertin Instruments), each cycle consisting of 23 seconds of homogenization at 
speeds of 6300 revolutions per minute (rpm). Samples were rested on ice for 2 minutes 
between cycles. After homogenization, cellular debris and lysing beads were precipitated by 
centrifugation and RNA isolated from the supernatant using RNeasy Mini Kit (Qiagen) as 
per manufacturer’s instructions.
Genome-wide transcriptional profiling and transcriptomic data repositories
Assessment of the transcriptome of TST and monocytes from patients in cohort 1 (active and 
latent TB) was performed by RNA-Seq. cDNA libraries were generated using the KAPA 
Hyperprep kit (Roche), and sequencing was performed on the Illumina Nextseq using the 
Nextseq 500 High Output 75 cycle kit (Illumina) according to manufacturers’ instructions, 
giving 15-20 million 41bp paired end- reads per sample. Mapping and generation of read 
counts per transcript were done using Kallisto (72). The R/Bioconductor package tximport 
was used to import the mapped counts data and summarize the transcript-level data into gene 
level data (73).
The TST transcriptome from active TB cohort 2 was derived directly from the data 
repository E-MTAB-3254 (ArrayExpress), and transcriptional profiling of individuals with 
cured TB was performed by microarray, as previously described (5).
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All transcriptomic data were log2 transformed. RNAseq data were presented as TPM 
(transcripts per million) to remove feature-length and library-size effects. Microarray data 
were cleaned and normalized as previously described (4, 5). All gene expression data were 
annotated with Human Genome Organisation Nomenclature Committee (HGNC) gene 
symbols. Principal component analysis (PCA) was performed as previously described (5). 
Differential gene expression was conducted in MultiExperiment Viewer v4.9 (http://
www.tm4.org/mev.html), using Mann-Whitney tests with a FDR<0.05. Pathway analysis 
was performed in InnateDB using the Reactome Pathway Database, and visualized as 
network diagrams in Gephi v0.8.2 beta (5). Upstream regulator analysis was performed 
using Ingenuity Pathway Analysis (Qiagen), focusing on cytokines with predicted activation 
z-score >3. The expression of transcriptional modules within genome-wide data was 
determined by calculating the geometric mean expression of all the module constituent 
genes found in the dataset being analyzed, using R scripts generated in our previous 
publication (21), which are available to download and use from the Github repository 
(https://github.com/MJMurray1/MDIScoring). Venn diagrams were constructed using the 
BioVenn tool (http://www.biovenn.nl/).
Gene expression module derivation and analyses
We used the immune cell modules immune cell modules “M37.1” (neutrophils), “M19” (T 
cells), “M69” (B cells) and “M7.2” (NK cells) that we previously that we previously 
identified to be most sensitive and specific for their respective annotations (21). Where 
indicated, relative neutrophil proportions were also estimated from TST samples using 
ABsolute Immune Signal (ABIS) deconvolution (22).
Keratinocyte (KC) cytokine-response modules were derived from published transcriptomic 
data (GSE12109 & GSE36287) of primary human KC stimulated with a selection of 
cytokines (14, 15). Significant transcriptional responses (paired t-test with α of p<0.05 
without multiple testing correction) of genes over-expressed >4-fold in the cognate cytokine 
condition relative to unstimulated KC were initially identified. Genes that were also 
upregulated > 2-fold by non-cognate cytokines compared to unstimulated KC were 
excluded. The KC IL-17 response module utilized a cut-off of 2-fold between IL-17 
stimulated KC and unstimulated KC as too few genes were upregulated >4-fold compared to 
unstimulated KC. The KC TNF-α response module generated in this way has already been 
published (6), but the other cytokine modules have not been previously described. The 
constituent genes of the KC modules are shown in Data file S2. Their specificity was 
evaluated in both the data from which they were derived and in independent data 
(GSE36287) of in vitro cytokine-stimulated KC (fig S2) (15).
‘Th’ subset modules were derived from published transcriptomic data of CD4+ T cells 
polarized towards different T helper phenotypes (GSE54627) (23). To derive specific 
modules for each differentiation state, we used gene expression from cells stimulated with 
anti-CD3 and anti-CD28. We initially identified an integrated list of genes induced in either 
Th1 or Th17 cells compared to unpolarized naïve T cells after anti-CD3 and anti-CD28 
stimulation using a paired t-test with α of p<0.05 without multiple testing correction. 
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Modules for each T helper phenotype were derived from this integrated list, identifying 
genes over-expressed in the phenotype of interest compared to all other conditions in the 
dataset (Th1, Th2, Th17 & T cells stimulated with IFN-γ). Each module was derived from 
the unique genes expressed >1.5-fold in the cognate condition compared to all other 
stimulation conditions. The gene components of Th1 and Th17 modules are available in 
Data file S2. Their specificity was evaluated in the dataset from which they were derived, in 
an independent dataset of polarized CD4 T cells, and in skin biopsies of patients with 
psoriasis vulgaris (fig. S4) (23–25).
An IL-1β-response module was derived from dataset cytokine stimulated fibroblasts (34) 
using an unpaired t-test with α of p<0.05 without multiple testing correction, and identifying 
genes induced >2-fold in IL-1β stimulated fibroblasts compared to TNF-α-stimulated 
fibroblasts. The gene components of this IL-1β bioactivity modules are available in Data 
File S3. The specificity of the module was evaluated in the dataset from which it was 
derived, in an independent dataset of IL-1β stimulated peripheral blood mononuclear cells 
(PBMCs) (Accession no: GSE40838) and in skin from individuals treated with recombinant 
IL-1 receptor antagonist, anakinra (Accession no: GSE27864) (35). An IL-6 response 
module was also used in the analyses presented (Fig 7). The derivation and extensive 
validation of this module was described previously (36).
PBMC stimulation
PBMCs were obtained by density gradient centrifugation of heparinized whole blood with 
Ficoll-Paque PLUS (GE Healthcare Biosciences) plated at a concentration of 1x106 cells/ml 
in RPMI-1640 supplemented with 5% heat-inactivated human AB sera for 16 hours, 
followed by 4 hours of stimulation with 10 μg/mL purified protein derivative (PPD) (SSI) or 
25 ng/ml PMA (Sigma) and 1 μg/ml ionomycin (Sigma), in conjunction with 10 μg/mL 
brefeldin A (Sigma).
Flow cytometry
PBMCs were stained with Live/Dead Fixable Blue Dead Cell Stain at a 1:1000 dilution 
(Invitrogen) for 30 minutes, and subsequently incubated with Human Trustain FcX 
(BioLegend) before cell surface staining at 4°C for 30 minutes with the following antibodies 
(all at a 1:100 dilution, obtained from BioLegend): CD3 (HIT3a), CD4 (SK3), CD8 (SK1). 
Cells were then fixed and permeabilized in Fixation Buffer and Intracellular Staining 
Permeabilization Wash Buffer (BioLegend) at 4°C for 20 minutes according to the 
manufacturer’s instructions. Quantification of intracellular cytokine was performed using 
antibodies to IL-17A (BL168) and IFN-γ (4S.B3), and associated isotype controls (all using 
a 1:100 dilution and obtained from BioLegend). Staining was performed at 4°C for 30 
minutes. Flow cytometry was performed with LSR Fortessa X20 (BD Biosciences), and data 
were analyzed with FlowJo (Tree Star).
Monocyte isolation and stimulation
In selected patients, PBMCs were isolated by density gradient centrifugation and CD14+ 
monocytes were isolated by positive selection magnetic cell sorting using CD14 MicroBeads 
(Miltenyi Biotec) as per manufacturer’s instructions (31). Monocytes were then cultured in 
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RPMI-1640 supplemented with 5% pooled human AB serum (Sigma) with and without 
stimulation with 100ng/ml PPD (SSI) for 4 hours. Total RNA from monocytes was collected 
using RLT buffer (Qiagen) and isolated using the RNeasy Micro kit (Qiagen)as per 
manufacturer’s instructions.
Immunostaining
Immunostaining of IL-17F was performed on 10 μm sections as previously described (74). 
Briefly, monoclonal mouse-anti-IL-17F at a 1:50 dilution (MA5-16229, Thermo Fisher 
Scientific) and 4′,6-diamidino-2-phenylindole (DAPI) (sc-24941, Santa Cruz 
Biotechnology) for detecting nuclei were used. Irrelevant primary antibodies from Sigma 
Aldrich (irrelevant mouse antibody, 1:50, code I8765) was applied at the same concentration 
of the related specific primary antibodies for immunostaining of negative control slides. 
Light-microscopic analysis was performed at a magnification of 40x with a Leica DM4000B 
microscope equipped with DFC-320 Leica digital camera (Leica Microsystems). Zeiss 
confocal microscope (LSM800) was used to acquire confocal images. Quantification of 
IL-17F was performed on 10x confocal images of samples through the measurement of 
mean grey value (MGV) using ImageJ (National Institutes of Health).
Immunostaining of MMP-1 was performed as previously described (75). Scanned slide 
images were obtained with use of NanoZoomer Digital Pathology System (Hamamatsu 
Photonics). Quantification of MMP-1 staining was performed blindly by extracting MMP-1 
associated 3, 3- diaminobenzidine (DAB) stain using standard deconvolution protocols in 
ImageJ (NIH). Cellular infiltrates were manually selected as depicted in Fig 2 and DAB 
stain quantified by staining intensity as proportion of the area selected using ImageJ. The 
selected region was moved without resizing to adjacent tissue that did not contain cellular 
infiltration to calculate background MMP-1 intensity. Three cellular infiltrates and 
background tissue regions were analyzed for each tissue samples. Six TST samples were 
quantified in each group.
Quantification of microbial load and radiographic scoring
Quantification of bacterial burden was estimated from two routinely used clinical diagnostic 
approaches: sputum smear scoring and the time for positive detection of Mycobacterium 
tuberculosis (Mtb) in liquid culture, a measure that is inversely associated with input 
bacterial count. Radiological severity scores were derived by estimating the percentage of 
the lung fields affected by abnormality, with an additional penalty for the presence of 
cavitation as previously described (71).
Statistical analysis
On scatter and violin plots, horizontal lines represent median values, and error bars reflect 
95% confidence intervals of median. Throughout the manuscript, values from two 
independent groups were compared by two-tailed Mann-Whitney test and p value of <0.05 
was interpreted as significant. Where indicated, a false discovery rate (FDR) adjusted p 
value was used to account for increased alpha from multiple testing. Correlations between 
variables were determined using 2 tailed Spearman’s rank correlation analyses. Associations 
between patient cohorts’ ethnic background and disease group were determined by Chi-
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squared test, whereas associations for variables with only two categories (sex and site of TB 
disease) were determined by Fisher’s exact test. For both of these contingency analyses, we 
interpreted a p value of <0.05 to indicate a significant association between the variables.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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In vivo IL-17A activity is elevated in active tuberculosis and may be a therapeutic target 
to attenuate disease-associated immunopathology.
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Figure 1. Enriched responses in the TST transcriptome of patients with active TB disease.
(A) Induration at the site of TST was measured in millimeters and recorded by routine 
clinical assessments in both populations. (B) Volcano plot depicting relationship between 
relative fold change (FC) in gene expression between active and latent TB and statistical 
significance (-log10 FDR adjusted p value). Red dots represent genes with significantly 
greater expression in active compared to latent TB. Grey dots represent the converse, with 
greater expression in latent TB. (C) Network diagram of Reactome pathways and genes 
over-expressed with > 1 log2FC in the TST of patients with active TB compared to latent 
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TB. Purple nodes represent Reactome database functional pathways, red nodes represent 
genes and edges reflect relationship between pathways and genes. Pathway node diameters 
are proportional to the respective pathway –log10 p value enrichment statistic. (D) 
Enrichment of selected gene transcripts within the TSTs of patients with active or latent TB 
relative to a separate cohort of individuals receiving a saline injection. Analyses were 
performed on samples from 48 and 191 participants with active or latent TB, respectively. 
Horizontal lines and error bars on scatter dot plots represent medians with 95% confidence 
interval. All p values were calculated by Mann-Whitney tests. MMP1, Matrix 
Metallopeptidase 1; DEFB4A, Defensin Beta 4A; CXCL1, C-X-C Motif Chemokine Ligand 
1; CXCL8, C-X-C Motif Chemokine Ligand 8; S100A9, S100 Calcium Binding Protein A9.
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Figure 2. IL-17 cytokines are over-expressed at the site of TST in individuals with active TB.
(A) Network diagram depicting upstream cytokine analysis of genes differentially expressed 
in TST of patients with active and latent TB. Red and black nodes represent significant 
genes overexpressed in active and latent TB, respectively. Yellow nodes represent predicted 
cytokines regulating the gene expression of red and black nodes. Edges depict relationship 
between upstream regulators and differentially expressed genes. IL, interleukin; IFN, 
interferon; TNF, tumor necrosis factor; GM-CSF, Granulocyte-Macrophage Colony-
Stimulating Factor; OSM, Oncostatin M (B) Enrichment of selected cytokine transcript 
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within the TSTs of active and latent TB patients relative to saline injection. Analyses 
performed on samples from 48 and 191 participants with active and latent TB, respectively. 
Violin plots represent frequency distribution of all samples, with bold and dashed lines 
representing median and quartile values. All p values were calculated by Mann-Whitney 
tests. IL17A, Interleukin 17A; IL17F, Interleukin 17F; OSM, Oncostatin M, IL6, Interleukin 
6; IL22, Interleukin 22.
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Figure 3. TST challenge in active TB is characterized by enrichment of IL-17A response and 
neutrophil-associated transcriptional modules.
(A) Analysis of gene expression from TST samples revealed enrichment in keratinocyte 
response modules of cytokine bioactivity. IL, interleukin; IFN, interferon; TNF, tumor 
necrosis factor. (B) Modules for neutrophils (Neut), T cells, B cells and NK cells revealed 
enrichment of neutrophil-associated genes in TST samples from individuals with active TB. 
Analyses were performed on samples from 48 and 191 participants with active and latent 
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TB, respectively. Horizontal lines and error bars on scatter dot plots represent medians with 
95% confidence interval. All p values were calculated by Mann-Whitney tests.
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Figure 4. Active TB is characterized by elevated Th17 cells at the site of TST.
(A) IL-17F immunohistochemistry (brown) in TST of patients with active TB. Black 
arrowheads point to mononuclear cells that express IL-17F and white arrowheads point to 
polymorphonuclear cells that do not express IL-17F. (B) Th17 and Th1 cell module 
enrichment in TST samples relative to saline injection in patients with active or latent TB. 
Analyses were performed on samples from 48 and 191 participants with active and latent 
TB, respectively. Horizontal lines and error bars on scatter dot plots represent medians with 
95% confidence interval. (C and D) Expression of T cells, Th17 cells, and IL-17A 
bioactivity modules from the site of human TB granulomata (n=5) relative to healthy lung 
tissue (n=2) (dataset GSE20050) (C) and in human Mtb-infected lymph nodes (LN) (n=9) 
relative to reactive lymph nodes that do not display evidence of granulomatous inflammation 
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or cancer (n=10) (D) (dataset E-MTAB-2547). Violin plots represent frequency distribution 
of all samples, with bold lines representing median values. All p values were calculated by 
Mann-Whitney tests.
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Figure 5. Complete antibiotic treatment for active TB attenuates IL-17A and Th17 responses at 
the site of TST.
(A) Induration at the site of TST was recorded in millimeters by routine clinical assessments 
in patients with active and cured TB. (B-D) Enrichment in TST samples relative to saline 
injection was observed for keratinocyte response modules of cytokine bioactivity (B), Th17 
and Th1 modules (C) and neutrophils and T cell modules (D). (A-D) Analyses performed on 
samples from 16 and 18 participants with active and cured TB, respectively. All p values 
were calculated by Mann-Whitney tests. Violin plots represent frequency distribution of all 
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samples, with bold and dashed lines representing median and quartile values. All p values in 
(A-D) were calculated by Mann-Whitney tests. IL, interleukin; IFN, interferon; TNF, tumor 
necrosis factor. (E) The relationship in active TB cohorts between either IL-17A cytokine 
bioactivity or Th17 module enrichment and days on TB treatment prior to TST assessment 
was evaluated. 48 and 16 active TB patients were assessed in cohorts 1 and 2, respectively. r 
and p values determined by Spearman rank correlation.
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Figure 6. Active TB is not characterized by enrichment of Th17 cells in blood.
(A) Expression of Th17 and Th1 modules in PPD-stimulated PBMC from patients with 
active or latent TB (n=4 in both groups) (data originated from dataset GSE27984). Violin 
plots represent frequency distribution of all samples, with bold and dashed lines representing 
median and quartile values. (B) Contour plots of CD3+CD4+ T cell intracellular staining for 
IFN-γ and IL-17A following PMA & ionomycin or PPD stimulation. Quadrant percentages 
represent proportion of total CD3+CD4+ T cell population. Top row (red) and bottom row 
(grey) are representative individuals with active and latent TB, respectively. (C) Summary 
data from experiments performed in (B), demonstrating proportion of IL-17A or IFN-γ 
expressing CD3+CD4+ or CD3+CD8+ T cells following stimulation with either PMA & 
ionomycin (io.) or PPD. Each dot represents an independent experiment. Horizontal black 
lines reflect median values for each group. Analyses performed on samples from 6 
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individuals each with active or latent TB from cohort 1. There were no statistical differences 
between any group by Mann-Whitney test.
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Figure 7. Elevated IL-1β and IL-6 induction by monocytes and cytokine activity in the TST in 
active TB.
(A) Venn diagram depicting genes significantly upregulated in PPD-stimulated monocytes 
relative to unstimulated monocytes from patients with active or latent TB (Mann-Whitney 
test with FDR < 0.05). (B) Fold change induction of selected cytokine transcripts in 
monocytes in patients with active (n=9) or latent TB (n=7) following PPD stimulation. (C) 
Quantitation of IL-1β and IL-6 secretion by ELISA from monocytes isolated from patients 
with active or latent TB following PPD stimulation. All samples plotted, with boxes 
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representing interquartile range and whiskers representing the full range of data. (D) 
Enrichment in TST relative to saline injection of IL-1β and IL-6 cytokine response modules. 
Analysis performed on samples from 48 and 191 participants with active or latent TB, 
respectively. Horizontal lines and error bars on scatter dot plots represent medians with 95% 
confidence interval. All p values were calculated by Mann-Whitney tests. IL1A, Interleukin 
1A; IL1B, Interleukin 1B; IL6, Interleukin 6; IL12A, Interleukin 12 Subunit Alpha; IL12B, 
Interleukin 12 Subunit Beta; IL23A, Interleukin 23 Subunit Alpha; TGFB2, Transforming 
Growth Factor Beta 2.
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Table 1
Patient cohort metadata.
Comparisons of age, gender and TST induration between active and cured TB participants performed by 
Mann-Whitney tests. Comparison in gender, ethnicity and site of disease performed by Chi-square tests. TST, 
tuberculin skin test; N/A, not applicable; IQR, interquartile range.
Cohort 1 (figs 1 to 4) TST Saline controls
Active TB Latent TB
Active versus 
Latent
Number 48 191 34
Received treatment for latent TB prior to 
TST
- 7 -
Age (median & range) 30.5 (19-77) 35 (18-65) p = 0.16 28 (18-75)
Gender Male (%) 63 46 p = 0.028 42
Female (%) 37 54 58
Ethnicity White (%) 43 27 p = 0.015 41
Black (%) 23 23 19
South American (%) 2 6 25
Asian (%) 28 21 25
Mixed (%) 4 22 6
Site of disease Pulmonary (%) 100 N/A - -
TST sampling from start of treatment 
(median & IQR)
19 (13-26) - - -
TST induration (median & range) 20 (0-70) 18 (0-47) p = 0.07 0 (all)
Cohort 2 (Fig 5) TST Saline controls
Active TB Cured TB Active versus Cured
Number 16 18 10
Age (median & range) 40 (25-71) 43 (20-60) p = 0.11 39 (18-54)
Gender Male (%) 62 61 p = 0.88 70
Female (%) 38 39 30
Ethnicity White (%) 14 23 p < 0.001 20
Black (%) 57 5 70
South American (%) 0 50 0
Asian (%) 19 11 10
Mixed (%) 10 11 0
Site of disease Pulmonary (%) 66 71 p = 0.45 90
Extrapulmonary (%) 34 29 10
TST sampling from start of treatment 
(median & IQR)
11 (5-28) - - -
Days from end of treatment (median & 
range)
- 76.5 (0-491) - -
TST induration (median & range) 20 (0-28) 19 (0-38) p = 0.64 0 (all)
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